Amylyx Pharmaceuticals, Inc. (AMLX) vs iRhythm Technologies, Inc. (IRTC)
A side-by-side comparison of Amylyx Pharmaceuticals, Inc. and iRhythm Technologies, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AMLX
Amylyx Pharmaceuticals, Inc.
$27.79HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
IRTC
iRhythm Technologies, Inc.
$107.19HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
Total return — AMLX vs IRTC
growth of $100 · dividends reinvested · last 5yAMLX +53.7% (+9.0%/yr)IRTC +2.9% (+0.6%/yr)AMLX compounded faster over this window
AMLX IRTC
AMLX vs IRTC: by the numbers
- •IRTC is the larger company ($3.52B vs $3.09B market cap).
- •Both run net losses; AMLX's is the smaller (0.00% vs -1.69% net margin).
Metrics side by side
Valuation
| Metric | AMLX | IRTC |
|---|---|---|
| P/S ratio | N/A | 4.27 |
| P/B ratio | 12.92 | 18.94 |
| EV / EBITDA | N/A | 286.34 |
| FCF yield | N/A | 1.11% |
Profitability
| Metric | AMLX | IRTC |
|---|---|---|
| Gross margin | 0.00% | 71.45% |
| Operating margin | 0.00% | -1.17% |
| Net margin | 0.00% | -1.69% |
| ROE | -63.59% | -7.50% |
| ROIC | -66.60% | -1.07% |
Growth (annualized)
| Metric | AMLX | IRTC |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 21.93% |
| Total return CAGR (5Y) | N/A | 12.95% |
Go deeper
Dig into the metrics
Amylyx Pharmaceuticals ROEiRhythm Technologies ROEAmylyx Pharmaceuticals operating marginiRhythm Technologies operating marginAmylyx Pharmaceuticals revenue growthiRhythm Technologies revenue growthAmylyx Pharmaceuticals free cash flowiRhythm Technologies free cash flow
Amylyx Pharmaceuticals & iRhythm Technologies appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.